Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the pancreas~* Prior failed 1st line gemcitabine therapy for metastatic disease or relapsed within six months of completion of gemcitabine adjuvant therapy~* Prior capecitabine or 5fu is allowed in the setting of radiation~* Must either be able to swallow or receive enteral nutrition via gastrostomy feeding tube~* Cardiac ejection fraction within institutional range of normal as measured by echocardiogram~* ECOG performance status 0-2~* Signed informed consent form~* Adequate hepatic, bone marrow, and renal function~Exclusion Criteria:~* Any prior treatment with lapatinib, or any anti-HER2 treatment or any anti-EGFR treatment~* Not recovered from adverse events to a toxicity grade \</= 1 due to prior chemotherapy~* More than one prior chemotherapy regimens~* Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis~* HIV positive on antiretroviral therapy~* Pregnant or lactating~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or capecitabine~* Malabsorption syndrome or uncontrolled inflammatory GI disease (Crohn's or ulcerative colitis)~* Known history of uncontrolled or symptomatic angina, arrhythmia, or congestive heart failure~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/ social situations that would limit compliance with study requirements~* Known dihydropyrimidine dehydrogenase deficiency~* Concurrent malignancy unless the subject has been curatively treated and disease free for \>/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer.~* Creatinine clearance \< 30 mL/min~* Absolute neutrophil count \< 1500, platelets \< 75,000~* Transaminases \> 3.0 times the upper limit of normal, except in known hepatic metastasis, wherein they must be \< 5.0 times the upper limit of normal~* Total bilirubin \> 1.5 times the ULN, \> 2.5 x ULN if patient has Gilbert's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Capecitabine (Type: EXPERIMENTAL): Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).